menu
    • menu
    [{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"ORAPHARMA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ORAPHARMA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ORAPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ORAPHARMA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ORAPHARMA \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ORAPHARMA

    Menu

    ORAPHARMA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Approved FDF

                            Sponsor : Bausch Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decreas...

                            Details : ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

                            Product Name : Arestin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Approved FDF

                            Sponsor : Bausch Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrea...

                            Details : Arestin® (minocycline hydrochloride) is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis, in adults with periodontitis.

                            Product Name : Arestin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arestin - Use in Subjects With Peri-Implantitis

                            Details : Minocycline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peri-Implantitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 27, 2012

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)

                            Details : Minocycline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peri-Implantitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2012

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth